SPY 120
Alternative Names: PR-022 - Spyre Therapeutics; SPY-120; SPY001-SPY002; SPY001/SPY002Latest Information Update: 26 Sep 2025
At a glance
- Originator Paragon Therapeutics
- Developer Paragon Therapeutics; Spyre Therapeutics
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Integrin alpha4beta7 antagonists; Tumour necrosis factor ligand superfamily member 15 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ulcerative colitis
- Preclinical Inflammatory bowel diseases
Most Recent Events
- 27 May 2025 Phase-II clinical trials in Ulcerative colitis in Ukraine, Moldova, Serbia and USA (IV) (NCT07012395)
- 27 May 2025 Phase-II clinical trials in Ulcerative colitis in Ukraine, Moldova, Serbia and USA (SC) (NCT07012395)
- 19 Feb 2025 Pharmacodynamics data from a preclinical study in Inflammatory bowel disease released by Spyre Therapeutics